Discovery of BI-2545: A Novel Autotaxin Inhibitor That Significantly Reduces LPA Levels in Vivo
作者:Christian A. Kuttruff、Marco Ferrara、Tom Bretschneider、Stefan Hoerer、Sandra Handschuh、Bernd Nosse、Helmut Romig、Paul Nicklin、Gerald J. Roth
DOI:10.1021/acsmedchemlett.7b00312
日期:2017.12.14
interventions addressing the unmet medical need of patients with idiopathic pulmonary fibrosis, we initiated a program to identify new autotaxin (ATX) inhibitors. Starting from a recently published compound (PF-8380), we identified several highly potent ATX inhibitors with improved pharmacokinetic and safety profiles. Further optimization efforts resulted in the identification of a single-digit nanomolar
为了寻找新的治疗干预措施来解决特发性肺纤维化患者未满足的医疗需求,我们启动了一项程序,以识别新的自分泌运动因子(ATX)抑制剂。从最近发表的化合物(PF-8380)开始,我们鉴定了几种具有改善的药代动力学和安全性的高效ATX抑制剂。进一步的优化工作导致鉴定出一位数的纳米摩尔铅化合物(BI-2545),该化合物在体内LPA显着降低,因此被认为是进行进一步研究的有价值的工具。